Therapeutic Exploratory (Phase II)

3,454 trials 1,368 recruiting

Filter these 3,454 trials by condition, country, sponsor and more.

Open in Search →

A phase 2 trial to study safety and efficacy of Capivasertib in patients with blood cancer where disease or cancer cell grows after a period… Ended

2024-516386-36-00 Relapsed or Refractory B-cell Non-Hodgkin Lymphoma 2022-03-04
Evaluation of the efficacy and safety of empagliflozin in the treatment of neutropenia in patients with glycogenosis Ib. EMPAtia. Ended

2024-512840-52-00 Glycogenosis type Ib is an ultra-rare disease, inherite 2022-03-03
Type of Access to the Blood Circulation During Cardiac Arrest Outside the Hospital Ended

2022-500744-38-00 Out-of-hospital cardiac arrest (OHCA) 2022-03-01
Safety and Efficacy of Efavaleukin Alfa in Subjects with Moderately to Severely Active Ulcerative Colitis Ended

2023-506004-93-00 Ulcerative Colitis (UC) 2022-03-01
Effect of antifibrotic therapy on regression of myocardial fibrosis after transcatheter aortic valve implantation (TAVI) in aortic stenosis … Ended

2024-510869-42-00 aortic stenosis patients with high fibrotic burden 2022-02-28
Inducta Ended

2023-509837-37-00 Patients with locally advanced T4 high risk prostate ca 2022-02-25
A study to test whether BI 706321 combined with ustekinumab helps people with Crohn's Disease Ended

2024-512756-38-00 Crohn`s Disease (CD) 2022-02-17
Isatuximab in type I cryoglobulinemia: A prospective pilot study ICE STUDY Ended

2024-515039-31-00 Isatuximab in type I cryoglobulinaemia: A prospective p 2022-02-10
FORMAT Study : Use of fibrinogen in the treatment of bleeding in thrombopenic patients after intensive chemotherapy refractory to platelet t… Ended

2024-516494-73-00 Hematological malignancy 2022-02-10
A Research Study, where the participant and healthcare providers are aware of the treatment being given, to evaluate safety and effectivenes… Ended

2022-501243-33-00 Diffuse Large B Cell Lymphoma (a type of non-Hodgkin’s 2022-02-03
Targeting ATR in soft-tissue sarcomas: a randomized phase II study Ended

2023-509499-41-00 Adult patients with locally advanced/unresectable and/o 2022-02-03
A Study to Evaluate the Efficacy and Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Ended

2023-507093-40-00 Chronic Obstructive Pulmonary Disease (COPD) 2022-01-27
Neoadjuvant Nivolumab and chemotherapy in stage I-II triple negative breast cancer. Ended

2024-512625-86-00 Early stage triple negative breast cancer 2022-01-27
Study to evaluate Pegcetacoplan in patients with TA-TMA after hematopoietic stem cell transplantation Ended

2023-510443-37-00 Transplant-associated Thrombotic Microangiopathy (TA TM 2022-01-26
VTX002 versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis Ended

2023-509233-39-00 Moderately to Severely Active Ulcerative Colitis 2022-01-20
A phase II trial of belimumab in combination with rituximab/venetoclax in patients with refractory or relapsed chronic lymphocytic leukemia Ended

2024-511474-68-00 refractory or relapsed chronic lymphocytic leukemia 2022-01-19
A Phase 2a study to evaluate, safety, tolerability, pharmacodynamic markers, and pharmacokinetics of AP-101 in patients with amyotrophic lat… Ended

2024-512343-23-00 Amyotrophic Lateral Sclerosis (ALS) 2022-01-12
A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Mu… Ended

2023-507189-17-00 Muscle-Invasive Urothelial Carcinoma of the Bladder 2022-01-09
Sotorasib (AMG 510) in Subjects with NSCLC with KRASG12C Mutation in Need of First-Line Treatment Ended

2024-511189-36-00 Non-small cell lung cancer (NSCLC) 2021-12-23
An Open-Label, Randomized, Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Pegcetacoplan in the Treatment of Post-Transplan… Ended

2024-511544-36-00 complement 3 glomerulopathy (C3G)/immune complex membra 2021-12-21
Obinutuzumab for primary membranous nephropathy: a pilot study in patients with rituximab-resistant or rituximab-dependent nephrotic syndrom… Ended

2024-515857-93-00 Primary Membranous Nephropathy 2021-12-17
An Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With Advanced Malignancies Previously Enrolled in… Ended

2023-503406-36-00 Male and female participants at least 18 years of age w 2021-12-13
Study of the use of the drug Thymosin alpha 1 in adults patients with Cystic Fibrosis. Ended

2024-518102-41-00 Cystic Fibrosis 2021-12-07
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Oc… Ended

2022-502542-28-00 Sickle Cell Disease 2021-12-06